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A retrospective  medical  record  review  was  conducted  to  identify  factors  from  veterinary
clinic medical  records  that may  have  contributed  to suspected  ineffectiveness  of  a heart-
worm preventive  product.  Patient  records  of  271  dogs,  comprising  301  instances  of  positive
heartworm  antigen  test  results  while  the  dogs  were  receiving  heartworm  preventive  were
evaluated.  Nineteen  veterinary  practices  in 17  counties  and  parishes  in  Arkansas,  Louisiana,
Mississippi,  and  Tennessee  participated  in the  study.  Records  were  selected  by the  veteri-
nary clinics  as  representative  of  cases  of suspected  lack  of  effectiveness  for a  heartworm
preventive,  and  for which  an  owner  satisfaction  claim  had  been  ﬁled with  the manufacturer.
Medical  record  data  were  entered  into  a software  program,  and a graphic  representation
was  created  to facilitate  analysis  of  whether  pet  owners  had  purchased  sufﬁcient  heart-
worm preventive  for  the  dog  to be compliant  during the  period  when  infection  with
Diroﬁlaria  immitis  could  have  led to the  positive  heartworm  antigen  test  result  for  that
patient  (“window  of infection”).  In 243  (80.7%)  cases,  there  was  insufﬁcient  heartworm
preventive  purchased,  leading  to a gap in protection  during  the  “window  of  infection”.  In
only  ﬁve  cases  (1.7%)  there  were  no purchase  lapses  or extenuating  circumstances  (under-
dosing  of  medication,  multiple  purchase  gaps  outside  the established  window  of infection,
or dogs  have  been  diagnosed  with  heartworm  infection  more  than  once  during  the  period
studied).  Half  the  cases  were  from  multiple-dog  households,  and  in many  of these house-
holds,  sharing  of product  between  pets  was  acknowledged.  In  another  28%  of  the  cases  from
multiple-dog  households,  more  product  was purchased  than  was  needed  for  one dog,  sug-
gesting  that the  product  was  being  shared  between  more  than  one  pet.  In most  cases,  there
was  at least  one  reason  that  a dog did not  receive  sufﬁcient  heartworm  preventive  product,
placing  the  dog  at risk  of  developing  an  infection  with  mature  heartworms.  Several  actions
were identiﬁed  that  veterinary  clinics  can  take  to improve  heartworm  disease  prevention
in their  patients.
©  2014  The  Authors.  Published  by  Elsevier  B.V.  This  is an  open  access  article  under  the  CC
Y-NC-NB∗ Corresponding author. Tel.: +1 919 971 6007; fax: +1 919 513 6336.
E-mail address: clarke atkins@ncsu.edu (C.E. Atkins).
http://dx.doi.org/10.1016/j.vetpar.2014.08.013
0304-4017/© 2014 The Authors. Published by Elsevier B.V. This is an open access
(http://creativecommons.org/licenses/by-nc-nd/3.0/).D  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. IntroductionHeartworm preventive medications belong to the
macrocyclic lactone class of drugs and are indicated for
the prevention of heartworm disease. Most products are
 article under the CC BY-NC-ND license
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esigned for monthly use, and product labels include lan-
uage that links the administration of product to the animal
eing exposed to mosquitoes. Both the American Heart-
orm Society and the Companion Animal Parasite Council
ecommend year-round administration of heartworm pre-
entives (American Heartworm Society, 2009; Companion
nimal Parasite Council, 2013), largely because attempting
o time the administration of heartworm preventive med-
cation precisely to mosquito risk is impractical and may
ermit a larval infection to mature to the adult stage.
In recent years, some veterinarians practicing in a region
f the United States comprising areas of Arkansas, western
ennessee, Mississippi, and Louisiana (referred together
s the Mississippi Delta, or the Delta) have reported an
ncreasing number of cases of dogs that tested heartworm
ntigen positive while receiving heartworm preventive
edication (Hartogenis, 2005). The reports have led to
peculation that Diroﬁlaria immitis has developed selec-
ional resistance to heartworm preventives (American
eartworm Society, 2010).
In recently reported studies, isolates of D. immitis with
ess than 100% susceptibility to heartworm preventive
roducts in an induced heartworm infection model have
een identiﬁed (Blagburn et al., 2013a,b). The relevance of
hese ﬁndings to ﬁeld cases of suspected lack of heartworm
reventive efﬁcacy has not been determined, but the risk
f selecting for D. immitis genotypes that confer reduced
usceptibility, particularly by repeated administration of
acrocyclic lactone products to dogs with patent heart-
orm infections, has been identiﬁed (Pulaski et al., 2013).
There are many reasons that a dog might test positive for
irculating D. immitis antigen while on a heartworm pre-
entive. The relationship between the heartworm lifecycle
nd the timing of testing and even the effect that heart-
orm preventives may  have on antigen release by mature
eartworms can affect testing outcomes and give the false
mpression that a particular product “failed” (American
eartworm Society, 2009). However, experts agree that
ost such cases are probably the result of a failure of
et owners to give heartworm preventive according to the
roduct label, allowing larval stages of D. immitis to mature
nto adult worms (Cummings et al., 1995; Bowman and
tkins, 2009; American Heartworm Society, 2010, 2012;
ompanion Animal Parasite Council, 2013). Nonetheless,
ome veterinarians practicing in the Delta insist that they
ave seen an increasing number of cases in which they
ere certain that owners were compliant in purchasing
nd administering heartworm preventive and yet dogs still
ested heartworm antigen positive (Bourguinat et al., 2011;
eary et al., 2011).
Heartworm preventive manufacturers offer customer
atisfaction programs, often referred to as “guarantees”,
hat provide different levels of support to veterinarians
or the treatment of dogs that test positive for circulating
eartworm antigen and for which heartworm preven-
ive product was dispensed to the pet owner. Criteria for
btaining assistance and the levels of support vary by man-
facturer but generally require that a dog be treated with
he manufacturer’s heartworm preventive product during
he previous year and that the dog have a prior negative
ntigen test. Provision of assistance does not indicate thatology 206 (2014) 106–113 107
a product failed, but all cases describing a suspected lack
of expected effect submitted to manufacturers must be
reported to regulatory authorities, according to local reg-
ulatory requirements. For example, in the United States,
these cases are reported to the Food and Drug Admin-
istration, Center for Veterinary Medicine (FDA CVM) as
suspected adverse drug events (coded as INEFFECT, HW
LARVAE).
The study reported here was conducted to determine
whether sufﬁcient heartworm preventive product was
available to dogs for which product failure was  suspected
and to identify factors from the medical records that may
have contributed to these dogs testing heartworm anti-
gen positive. Indeed, the results of the study reported
herein strongly indicate that the vast majority of lack of
expected effects are associated with failure of dog owners
to purchase adequate product to meet recommendations
for heartworm prevention. Characterizing factors that the
veterinary practice or pet owners can control may  lead to
actions that can reduce the number of dogs developing
heartworm disease.
2. Materials and methods
2.1. Case selection
Patient case records from veterinary practices were
reviewed. The principal investigator visited 19 veteri-
nary practices in 17 counties and parishes in Arkansas,
Louisiana, Mississippi, and Tennessee. Clinics were selected
on the basis of having submitted heartworm preventive
guarantee claims, willingness to provide records to the
investigator, dispensed more than one heartworm preven-
tive product, and perceived that they had a lack of expected
effect of heartworm preventives in some of their patients.
The veterinary practices selected the patient records to
be reviewed and chose cases that they considered to rep-
resent lack of expected effect. These cases were those that
had been submitted to a manufacturer for assistance and
for which the clinic believed that the dog had received the
recommended heartworm preventive medication, which
for all clinics was  every month, year-round.
2.2. Data collection
Information was  taken from patient charts and practice
management transaction records. Records of other dogs
in the household were reviewed when indicated (e.g.,
when there were unusual purchase histories in the med-
ical record of the dog of note, suggesting the possibility
of product sharing; when multiple dogs shared the same
paper medical record; when there were long lapses in pre-
ventive purchase that could have been negated by purchase
on another dog’s record; when the paper medical record
indicated that a purchase was for more than one dog). Addi-out and taken into account. Data were entered into a com-
puterized form (FLASH® CS3, Adobe Systems Incorporated,
San Jose, CA) linked to software application, the window of
infection (WOI) tool (www.heartwormedu.com).
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2.3. Analyses
The WOI  tool creates a graphic temporal depiction of
the relationship between purchase dates, number of doses
purchased, heartworm antigen test results, and the prob-
able period of time that dogs would have been infected to
give the recorded test results. Collected data included the
following:
• Dog name/number
• Clinic name
• Dog’s date of birth
• Dog’s body weight
• Heartworm antigen test dates and results, starting with
the most recent positive test result and including up to
two previous test results. Positive results were conﬁrmed
at a commercial laboratory and were considered to reﬂect
adult D. immitis infection.
• Heartworm preventive purchase history, including prod-
uct, date of purchase, number of doses purchased, and
number of dogs treated with each purchase
• Other information included whether the patient was  in
a multiple-dog household if the patient was stated to be
in a single-dog household but the number of doses pur-
chased exceeded the needs of one pet and date of prior
diagnosis or treatment for heartworms.
The WOI  tool creates a timeline along which heartworm
antigen test results, heartworm preventive purchases,
and presumed heartworm preventive administration are
shown. Figs. 1–3 illustrate how the WOI  tool uses and ana-
lyzes the collected data. The program assumes that the
purchased heartworm preventive was given every 30 days
(or 6 months, in the case of moxidectin injectable), start-
ing the day that product was purchased. It assumes that
all antigen test results are correct. The program deﬁnes the
“window of infection” as the time frame during which a
dog would have been infected with D. immitis so as to result
in the recorded testing outcomes. The WOI  is determined
by the dates of the most recent positive test and the most
recent prior negative test. The WOI  extends from 6 months
prior to the most recent positive test to 9 months before
the most recent negative test. These boundaries of the WOI
are based on the lifecycle of D. immitis and the time after
infection at which female worms may  be detected by anti-
gen tests (Bowman and Atkins, 2009; American Heartworm
Society, 2012). This period includes the effect that macro-
cyclic lactone administration may  have on delaying the
time-point when antigen may  be detected from maturing
female worms (American Heartworm Society, 2009). For
cases in which only one test (positive) was done, a “nega-
tive” test result is entered for when the dog was 6 months
old, so that the WOI  extends back to the date of birth of the
dog. Calculated gaps in the purchase of heartworm preven-
tive greater than 45 days are highlighted in red along the
timeline. These gaps depict the most likely period of time
when a dog may  have been infected with D. immitis larvae,
which subsequently resulted in a positive heartworm anti-
gen test. The gaps do not indicate precisely when a dog was
infected or that it was certainly infected during that time
frame. Also, within a highlighted gap, it is assumed thatology 206 (2014) 106–113
new infections acquired within 30 days prior to the next
administration of heartworm preventive were prevented
from reaching maturity.
Several assessments were made based on the analysis
of the case record data and the presence of purchase gaps
within the WOI. Positive dogs were assessed as having a
“pre-detectable” infection if greater than 2 months of age
and/or had no prior history of heartworm preventive when
it received its ﬁrst recorded prescription of heartworm pre-
ventive (Fig. 2). If this purchase gap occurred during the
time from birth until the ﬁrst recorded prescription, the
cases were further deﬁned as “puppy” cases. An assess-
ment of a purchase gap within the WOI  was made for cases
in which there had been prior heartworm preventive pur-
chase, but there were gaps greater than 45 days between
the calculated last dose of a prior purchase and the ﬁrst
dose of the next purchase (Fig. 3). The remaining cases were
given an assessment of “no gap in WOI”. Additional obser-
vations that were recorded, based on the WOI  graph, were
purchase gaps outside of the WOI  or complete absence of
purchase gaps.
It was  also noted and recorded for each heartworm
diagnosis whether the dog under review was  from a
multiple-dog household; whether heartworm preventive
purchases was appropriate for the number of dogs in the
family; prior diagnosis or treatment for heartworms; and
whether the product size was  insufﬁcient for dog’s body
weight.
To determine whether this non-randomized sample of
heartworm infections was representative of the partici-
pating clinics, as well as Delta clinics more broadly, the
results from these 301 heartworm infections in 271 dogs
were compared to the results of similar analyses from a
larger database of cases submitted to Merial as part of
the PLUS® Guarantee customer satisfaction program by
practices throughout the Delta states from the years 2007
through mid-2010. The results from the clinic records
reviews were compared to this larger data set by deter-
mining the 95% conﬁdence limits of the larger data set for
the proportions of pre-detectable infections, purchase gaps
in the WOI, purchase gaps in the WOI  plus pre-detectable
infections, and cases with no gaps in the WOI  time period.
3. Results
A total of 319 heartworm infections were examined
in which there was  a positive heartworm antigen test
while the dog was putatively receiving a heartworm
preventive. Eighteen dogs were excluded from interpre-
tation because too many dogs in the household made
accurate interpretation of medical records impossible,
multiple owners were involved, or there was insufﬁcient
or conﬂicting information. Case records from 271 dogs
with 301 distinct instances of a positive heartworm anti-
gen test were then reviewed and assessed. Cases came
from the years 2004–2011, with 75% of cases coming from
2009 and 2010. Heartworm preventives noted in these
case records included ivermectin/pyrantel (HEARTGARD®
Plus, Merial Limited, Duluth, GA) (244 cases), generic iver-
mectin/pyrantel products (12 cases), milbemycin oxime
(INTERCEPTOR®, Novartis Animal Health, Greensboro, NC)
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Fig. 1. Graphic output from the Window of Infection tool. The asterisks above the timeline indicate when preventive product was  purchased. The small
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ine). (For interpretation of the references to color in this ﬁgure legend, th
84 cases), moxidectin (PROHEART 6®, Pﬁzer Inc., Madison,
J) (15 cases), moxidectin/imidacloprid (ADVANTAGE-
ulti®, Bayer Animal Health, Shawnee, KS (5 cases),
ilbemycin oxime/lufenuron (SENTINEL®, Novartis Ani-
al  Health) (3 cases), selamectin (REVOLUTION®, Pﬁzer
nc) (2 cases), and “other” heartworm preventive products
4 cases). Two hundred and thirty-ﬁve cases involved dogs
hat had only one instance of testing heartworm-positive,
nd 66 cases involved 31 dogs from which two or more
nstances of testing heartworm-positive infections were
eviewed.
From the analyses of all 301 heartworm diagnoses, gaps
n heartworm preventive purchase within the WOI  were
dentiﬁed in 244 (80.7%), including 38 pre-detectable gaps,
77 purchase gaps, 28 pre-detectable and purchase gaps;
able 1). Of the 66 cases assessed as “pre-detectable” or
pre-detectable and purchase gaps”, 59 were classiﬁed as
puppy cases” in which a dog was started on heartworm
reventive later than 2 months after birth. Of the remaining
 cases, 3 involved dogs adopted from a shelter and 4 were
everal years old before they received heartworm preven-
ive.In 58 (19.3%) cases, there were no gaps in heartworm
reventive purchase within the WOI. Of these 58 cases, 42
ad purchase gaps outside the WOI  and 16 (5.3%) had no
urchase gaps at all in the period reviewed. Of those 16d to allow compliance. In this case, there is a 9-month purchase gap (red
r is referred to the web  version of this article.)
cases with no purchase gaps, only 5 (1.7%) had no purchase
gaps and no factors that could inﬂuence or indicate insuf-
ﬁcient administration of heartworm preventive, including
prior diagnosis with or without treatment for heartworm
infection; substantial purchase gaps outside the WOI  +/−
multiple heartworm infections; or insufﬁcient product size
used (underdosed).
Among all 301 cases, there were 153 cases from
multiple-dog households, 43 cases in which too many
doses were purchased for only one dog, 80 cases in which
heartworm infections had been previously diagnosed or
treated, and 12 cases in which dogs were provided an insuf-
ﬁcient amount of heartworm preventive for their body
weights.
The results for the assessments of pre-detectable, pur-
chase gap, purchase gap plus pre-detectable, and unknown
from the 301 cases reported here all fell within the 95% con-
ﬁdence limits of results from the larger database of cases
submitted to Merial Limited as part of the PLUS® Guarantee
customer satisfaction program, including cases submitted
from the 19 clinics from our study and from a larger number
of clinics throughout the Delta (data on ﬁle, Merial Limited,
Duluth, GA). Therefore, the results reported here appear
to be representative of suspected heartworm preventive
lack of efﬁcacy cases reported by veterinary practices in
the Delta.
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Fig. 2. Pre-detectable case in a puppy (classiﬁed by authors as a puppy case). The dog was  born 8/8/2009, and it received its ﬁrst heartworm preventive
t for this
rogramdose  on 10/31/2009, when it was 2.5 months old. The ﬁrst heartworm tes
does  represent an actual blood test, but was inserted as required for the p
4. Discussion
The role of owner and/or veterinary compliance in cases
of suspected heartworm preventive lack of efﬁcacy was  the
focus of this study. We  used a novel computer program
and detailed medical record examination to assess com-
pliance based on purchase history of macrocyclic lactones.
We found that the vast majority of dogs for which customer
satisfaction claims were ﬁled not only had inconsistent pre-
ventive history, but in 80.7%, there were product purchase
gaps of >45 days within the WOI, a time when infection
with D. immitis might well have led to the observed posi-
tive heartworm antigen test results. Of the remaining cases,
most had one or more factors that could have disrupted
the continuity of the dog receiving sufﬁcient heartworm
preventive every 30 days. Of these 301 the cases, there
were only ﬁve in which the owner had purchased sufﬁ-
cient preventive doses and in which no disrupting factors
were evident from the medical records.
The WOI  tool was a powerful aid in assessing possible
reasons for dogs testing heartworm antigen positive, even
though they had been on a heartworm preventive. It can
be difﬁcult to review medical records for product purchase
and testing histories and to determine whether there was
a period during which the dog was not protected. Utiliz-
ing the WOI  tool, when preventive purchase is inadequate, dog was  in October 2010. The negative test result shown on the timeline
 to ﬁnish the graphic the window of infection display.
one can see clear gaps in purchase history prior to the
last negative testing, when the dog was  unprotected and
when infection that caused its testing outcome probably
occurred.
In the majority of cases, the purchase of “name-brand”
(ﬁrst patented) ivermectin/pyrantel (HEARTGARD® Plus),
milbemycin (INTERCEPTOR®), milbemycin/lufenuron
(SENTINEL®) was noted in the practice management trans-
action statement and hand-written medical record. While
the investigators did not request cases in which speciﬁc
products were used, the proportion of cases receiving
these products likely reﬂects the share of these products in
the participating clinics and that the clinics were recruited
by Merial representatives. The cases evaluated in this
study were only those that tested heartworm antigen-
positive and for which owner satisfaction claims were
ﬁled. Therefore, factors, such as multiple dog households,
excessive doses purchased for one dog (in our experience,
a proxy for multiple dogs, product sharing, and potential
missed doses), and previous treatment for heartworm
disease were impossible to consider as risk factors, because
there was no control population with which to compare.
Nonetheless, based on the ﬁndings of this study, there are
speciﬁc recommendations that the authors believe will
help reduce the number of dogs developing heartworm
disease.
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ntigen test result. There is also a 6-month period in 2010 during which t
.1. Start puppies on a heartworm preventive by 6–8
eeks of age
Mosquitoes can feed on a dog of any age, so puppies
re at risk for being infected by D. immitis from birth. The
merican Heartworm Society recommends that puppies
e started on a heartworm preventive as soon as possi-
le, but no later than 8 weeks of age (American Heartworm
ociety, 2012). Until then, puppies should be kept indoors
r in screened protection to reduce mosquito exposure.
.2. Actively help owners avoid purchase gaps for
eartworm preventives
Dogs that miss one or more doses of their monthly
eartworm preventive are at increased risk of develop-
ng heartworm disease. Gaps in prevention are believed
o be the most common reason dogs receiving preventive
evelop mature heartworm infection (Companion Animal
arasite Council, 2012). Forgetting to re-purchase heart-
orm preventives at the appropriate time is easy to do,
ut it is also avoidable. Veterinary staff members can check
atients’ records to send or call with reminders and deter-
ine what the dog needs prior to its annual examination.
hone “apps” can be utilized to remind clients when it
s time to repurchase. Also, pet owners who purchase this case, but the owner had purchased heartworm preventive for the 15
on that the dog had sufﬁcient heartworm preventive prior to the positive
er purchased 6 more doses than needed for this dog.
12-packs of monthly heartworm preventive are more likely
to re-purchase on time than owners who purchase 6-packs
or individual doses[12].
4.3. Make sure heartworm preventives are dispensed
speciﬁcally for each dog in the family
Multiple-dog households are prime candidates for pre-
vention lapses because clients often share heartworm
preventives between dogs. This sharing can result in missed
doses or in a dog not receiving the proper product for its
weight. Emphasize to pet owners the importance of each
dog having its own prescription and note the product dis-
pensed on its own  medical record to mitigate improper
dosing and prevention gaps. Treating all dogs in a house-
hold on the same day likely improves compliance.
4.4. Give special attention to any dog previously treated
for heartworm disease
If a dog has been previously treated for heartworm dis-
ease, especially if it was  due to a gap in preventive purchase,
the owner should receive education and tips on how to
ensure uninterrupted purchase of preventive. Even though
a dog might have tested heartworm negative after treat-
ment, missed doses around the time of treatment could
112 C.E. Atkins et al. / Veterinary Parasit
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result in another heartworm infection that would not be
detectable for several months.
4.5. Test dogs annually
Dogs should be tested annually for heartworm infec-
tion, using an antigen test [5]. Dogs younger than 7 months
of age need not be tested because the antigen test only
detects only adult female heartworms. A negative heart-
worm test does not guarantee the absence of (pre- or
undetectable) infection; it only means that no adult heart-
worms  were detected. The dog may  have developing larval
stages, immature adult worms, or even a small number of
mature worms. Re-testing the dog at an appropriate inter-
val, based on its prior history and season, is a vital part of
its heartworm prevention program.
4.6. Advise owners to administer heartworm preventive
to their pet every 30 days, rather than “monthly”
Help them set up a system to remind them to administer
the heartworm preventive, which can include the use of
available smart phone applications.
As with most retrospective case studies that are based
on veterinary clinics’ medical record reviews, this study
has certain limitations. First, the diagnosis of heartworm
infection was based on the antigen test and not proven
by necropsy. Nevertheless, the antigen test is considered
to be the gold standard for heartworm testing in living
animals, and each positive test was  conﬁrmed in a com-
mercial laboratory for the customer satisfaction guarantee.
It was  impossible to determine whether pets received the
prescribed medication, retained the medication, or had
topically applied medication displaced by bathing or swim-
ming. Likewise, although great effort was employed to
discover alternative sources, it was  impossible to abso-
lutely exclude the possibility of product having been
purchased elsewhere, which could, of course, effectively
close the purchase gap within the WOI.
5. Conclusion
The study reported here was  not designed to prove or
disprove the existence or the possibility of the develop-
ment of selectional resistance to heartworm preventives by
migrating larval stages of D. immitis. However, with careful
scrutiny of the medical records from 301 cases of heart-
worm infection in dogs residing in the Mississippi Delta
region, we found that, in the vast majority of cases, factors
others than product lack of efﬁcacy, were associated with
LOE claims. The heartworm infections we report herein
occurred in dogs whose owners and veterinarians felt that
compliance was  “perfect” and ﬁled customer satisfaction
claims with the companies which produced the product
being used. As with several other reports (Cummings, et al.,
1996; Anonymous, 2002; American Heartworm Society,
2012; Companion Animal Parasite Council, 2012), our study
demonstrates that compliance, even for those considered
to be dedicated, concerned clients, frequently breaks down.
Knowing which factors contribute to puppies and dogs
receiving insufﬁcient protection from heartworm infection
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